Paris, France, 22 January 2008 -- Novexel, the pharmaceutical company focused on the discovery and development of novel antibacterials and anti-fungals, announces that it has entered into an agreement with Forest Laboratories Holdings Limited, a wholly owned subsidiary of
Forest Laboratories, Inc. (NYSE : FRX), for the development, manufacture and commercialization of Novexel’s novel
intravenous beta lactamase inhibitor, NXL104 in combination with Forest’s ceftaroline...
Novexel's Press Release -
Communiqué de Presse de Novexel-
